Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1129)	6/6/2003 9:18:21 AM
From: quidditch	Read Replies (1) \| Respond to of 1834

Erik, The abstracts that were posted on NBIX's website did not look to me to contain anything dramatically different from previously disclosed results of indiplon trials. There was also a reference to a banker's conference at which Neurocrine was to present. Did anyone listen to that? Just trying to understand the pop yesterday, unless it's NBIX playing valuation catch-up with some of the other movers, albeit those in different states of BT development. (Looks like the stock will be giving back some of the move.) quid